

David P Sonne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4740441/publications.pdf>

Version: 2024-02-01

28
papers

872
citations

623188

14
h-index

525886

27
g-index

29
all docs

29
docs citations

29
times ranked

1504
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical relevance of the bile acid receptor TGR5 in metabolism. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 224-233.	5.5	105
2	Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3002-3009.	1.8	100
3	Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. <i>JCI Insight</i> , 2018, 3, .	2.3	86
4	Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. <i>CMAJ Open</i> , 2014, 2, E162-E175.	1.1	73
5	Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 918-927.	1.2	72
6	MECHANISMS IN ENDOCRINOLOGY: Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. <i>European Journal of Endocrinology</i> , 2014, 171, R47-R65.	1.9	62
7	Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. <i>European Journal of Endocrinology</i> , 2014, 171, 407-419.	1.9	56
8	Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 955-961.	2.2	50
9	Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G413-G419.	1.6	43
10	Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2017, 5, CD012204.	1.5	31
11	Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2557-2564.	2.2	28
12	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2076-2083.	1.8	24
13	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. <i>Metabolic Syndrome and Related Disorders</i> , 2018, 16, 530-536.	0.5	22
14	Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1623-1631.	2.2	21
15	Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. <i>Gastroenterology</i> , 2019, 157, 569-571.	0.6	16
16	Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A review. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1214-1222.	2.2	14
17	MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases. <i>European Journal of Endocrinology</i> , 2021, 184, R193-R205.	1.9	14
18	Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 603-612.	1.3	12

#	ARTICLE	IF	CITATIONS
19	Pancreatic Amylase and Lipase Plasma Concentrations Are Unaffected by Increments in Endogenous GLP-1 Levels Following Liquid Meal Tests. <i>Diabetes Care</i> , 2015, 38, e71-e72.	4.3	11
20	Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00257.	1.3	8
21	What is on the horizon for type 2 diabetes pharmacotherapy? â€“ An overview of the antidiabetic drug development pipeline. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1253-1265.	2.5	6
22	Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. <i>Diabetes Care</i> 2015;38:1858â€“1867. <i>Diabetes Care</i> , 2015, 38, e215-e215.	4.3	5
23	Postprandial Plasma Concentrations of ProANP in Patients with Type 2 Diabetes and Healthy Controls. <i>Clinical Chemistry</i> , 2017, 63, 1040-1041.	1.5	5
24	Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption. <i>BMJ Open</i> , 2021, 11, e044711.	0.8	3
25	On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes. <i>Endocrine Connections</i> , 2014, 3, 193-199.	0.8	2
26	Effect of single doses of citalopram and reboxetine on urethral pressure: A randomized, double-blind, placebo- and active-controlled three-period crossover study in healthy women. <i>Neurourology and Urodynamics</i> , 2022, 41, 1482-1488.	0.8	2
27	Restoration of enteroendocrine and pancreatic function after internal hernia and short bowel syndrome in a young woman with gastric bypass - a 2-year follow-up. <i>Physiological Reports</i> , 2018, 6, e13686.	0.7	1
28	Cardiovascular effects of alpha-linolenic acid â€“ a possible role of glucagon-like peptide-1. <i>Experimental Biology and Medicine</i> , 2013, 238, 1116-1117.	1.1	0